The frequency of nivolumab treatments, also known as Opdivo, can vary depending on the specific condition being treated and the individual patient's response to the medication. According to the prescribing information for nivolumab [1], it can be administered as a standalone treatment or in combination with other immunotherapy agents.

In patients with melanoma, nivolumab is typically administered as a 240-mg intravenous infusion every 2 weeks, for 2 years or until disease progression or unacceptable toxicity [2]. This dosing regimen has been shown to provide sustained clinical benefit and improved overall survival in patients with advanced melanoma [3].

In patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma, nivolumab is typically administered as a 240-mg intravenous infusion every 2 weeks. The treatment duration varies depending on the patient's response, with some patients receiving treatment for up to 2 years or until disease progression or unacceptable toxicity [4].

It's worth noting that the dosing and frequency of nivolumab treatment may be adjusted based on the patient's response to the medication, as well as any adverse effects that may occur. The frequency of administration may be reduced or the dose may be decreased in patients who experience side effects [5].

For more information on the dosing and administration of nivolumab, please refer to the prescribing information or consult with a healthcare professional. You can find more information on nivolumab on websites like DrugPatentWatch.com [6].

Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514s015lbl.pdf
[2] https://www.nature.com/articles/s41416-020-00855-4
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1101672
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311115/
[5] https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1422
[6] https://www.drugpatentwatch.com/drugs/opdivo-2635